Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD

References

• DecramerMJanssensWMiravitllesMChronic obstructive pulmonary diseaseLancet201237998231341135122314182
   PubMed Web of Science ®Google Scholar
• HoggJCMcDonoughJESuzukiMSmall airway obstruction in COPD: new insights based on micro-CT imaging and MRI imagingChest201314351436144323648907
   PubMed Web of Science ®Google Scholar
• BarnesPJNew anti-inflammatory targets for chronic obstructive pulmonary diseaseNat Rev Drug Discov201312754355923977698
   PubMed Web of Science ®Google Scholar
• VestboJHurdSSAgustiAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• BabuKSKastelikJAMorjariaJBInhaled cortiocsteroids in COPD: a pro-con perspectiveBr J Clin Pharm2014782282300
   PubMed Web of Science ®Google Scholar
• PavkovRMuellerSFiebichKCharacteristics of a capsule based dry powder inhaler for the delivery of indacaterolCurr Med Res Opin201026112527253320843166
   PubMed Web of Science ®Google Scholar
• Combivent^® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol Prescribing InformationBoehringer Ingelheim2012 Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Combivent+Respimat/CMVTRSPT.pdfAccessed January 31, 2014
   Google Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEEffects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPDChest2006129350951716537846
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• SechaudRRenardDZhang-AubersonLMotte SdeLDrollmannAKaiserGPharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD)Int J Clin Pharmacol Ther201250211812822257577
   PubMed Web of Science ®Google Scholar
• Ali-MelkkilaTKantoJIisaloEPharmacokinetics and related pharmacodynamics of anticholinergic drugsActa Anaesthesiol Scand19933776336428249551
   PubMed Web of Science ®Google Scholar
• BarnesPJMuscarinic receptor subtypes in airwaysLife Sci1993525–65215278441331
   PubMed Web of Science ®Google Scholar
• SykesDADowlingMRCharltonSJExploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptorMol Pharmacol200976354355119498041
   PubMed Web of Science ®Google Scholar
• SykesDADowlingMRLeighton-DaviesJThe influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropiumJ Pharmacol Exp Ther2012343252052822854200
   PubMed Web of Science ®Google Scholar
• MoenMDIndacaterol: in chronic obstructive pulmonary diseaseDrugs201070172269228021080743
   PubMed Web of Science ®Google Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther201023425726720381630
   PubMed Web of Science ®Google Scholar
• RocheNChanezPBronchodilator combinations for COPD: real hopes or a new Pandora’s box?Eur Respir J20134261441144524293415
   PubMed Web of Science ®Google Scholar
• CazzolaMSegretiAMateraMGNew developments in the combination treatment of COPD: focus on umeclidinium/vilanterolDrug Des Devel Ther2013712011208
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev201264345050422611179
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyUltibro Breezhaler: European Medicines Agency assessment report2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002679/WC500151257.pdfAccessed December 8, 2013
   Google Scholar
• Novartis Europharm LtdSeebri Breezhaler (glycopyrronium bromide) powder for inhalation: EU summary of product characteristics2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002430/WC500133769.pdfAccessed December 8, 2013
   Google Scholar
• SechaudRSudershanMPerrySEfficient deposition and sustained lung concentrations of NVA237 after inhalation via the Breezhaler device in manEur Respir J201240Suppl 56P4839
   Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• KerwinEHebertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• D’UrzoAKerwinEOverendTD’AndreaPChenHGoyalPOnce daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studiesCurr Med Res Opin201430349350824156566
   PubMed Web of Science ®Google Scholar
• BeehKMSinghDDi ScalaLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J Chron Obstruct Pulmon Dis2012750351322973092
   PubMed Web of Science ®Google Scholar
• SekiyaMKawayamaTFukuchiYSafety and efficacy of NVA237 once daily in Japanese patients: the GLOW4 trialEur Respir J201240Suppl 56P2103
   Google Scholar
• ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med2014141424438744
   PubMed Web of Science ®Google Scholar
• WalterVGoyalPJackDChenHHenleyMMcbryanDCo-administration of glycopyrronium and indacaterol improves lung function and symptoms in patients with COPD versus indacaterol alone: the GLOW6 studyThorax201368A181A182P232
   Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• MahlerDDecramerMD’UrzoASuperior lung function with once-daily QVA149 translates into improvements in patient reported breathlessness compared with placebo and tiotropium in COPD patients: the BLAZE studyAm J Respir Crit Care Med2013187A6070
   Web of Science ®Google Scholar
• BeehKMKornSBeierJQVA149 once daily improves exercise tolerance and lung function in patients with COPD: the BRIGHT studyThorax201267Suppl 2P191
   Web of Science ®Google Scholar
• DahlRChapmanKRRudolfMSafety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN studyRespir Med2013107101558156723867808
   PubMed Web of Science ®Google Scholar
• DahlRJadayelDAlagappanVKChenHBanerjiDEfficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyInt J Chron Obstruct Pulmon Dis2013850150824159259
   PubMed Web of Science ®Google Scholar
• RodrigoGJPlazaVEfficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium (Qva149) for the treatment of COPD: a systematic reviewChest2014146230931724556877
   PubMed Web of Science ®Google Scholar
• WelteTVogelmeierLDahlROnce-daily QVA149 has a good safety profile in patients with COPDEur Respir J201342Suppl 57P757
   Google Scholar
• LuYChenHD’AndreaPBanerjiDOnce-daily QVA149 shows no increase in the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events, and mortality compared with placebo: a network meta-analysis across multiple safety databasesAm J Respir Crit Care Med2013187A1486
   Web of Science ®Google Scholar
• SinghDNew combination bronchodilators for COPD: current evidence and future perspectivesBritish Journal of Clinical Pharmacology2014
   Web of Science ®Google Scholar